Molecular Imaging of Pulmonary Fibrosis
- Margaret B Allison 1,2, Ciprian Catana 3,4,5, Iris Y Zhou 3,4,5, Peter Caravan 3,4,5, Sydney B Montesi 6,2
- Margaret B Allison 1,2, Ciprian Catana 3,4,5, Iris Y Zhou 3,4,5
- 1Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts.
- 2Department of Medicine, Harvard Medical School, Boston, Massachusetts.
- 3Department of Radiology, Harvard Medical School, Boston, Massachusetts.
- 4A.A. Martinos Center for Biomedical Imaging, Boston, Massachusetts; and.
- 5Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts.
- 6Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts; sbmontesi@mgb.org.
- 0Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts.
|
February 27, 2025
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Molecular imaging offers a noninvasive way to track fibrotic lung disease progression. This review discusses novel imaging probes and challenges in developing them for better diagnosis and drug development.
Area Of Science
- Pulmonary Medicine
- Molecular Imaging
- Biotechnology
Background
- Fibrosing lung diseases impact over 160,000 people in the US, often with a poor prognosis.
- Current antifibrotic therapies only slow disease progression, highlighting the need for improved treatments.
- Molecular imaging allows in-vivo visualization of disease processes, offering a noninvasive approach to monitor fibrotic pathways.
Purpose Of The Study
- To review molecular imaging probes currently under development for pulmonary fibrosis.
- To discuss challenges in translating preclinical molecular imaging research into clinical applications.
- To explore future directions for utilizing molecular imaging in drug development for fibrotic lung diseases.
Main Methods
- Literature review of molecular imaging probes for pulmonary fibrosis.
- Analysis of current challenges in clinical translation of imaging agents.
- Discussion of future prospects for molecular imaging in pharmaceutical research.
Main Results
- Several molecular imaging probes are in development for pulmonary fibrosis.
- Significant hurdles exist in translating preclinical probes to clinical use.
- Molecular imaging holds promise for improved diagnosis and monitoring of fibrotic lung diseases.
Conclusions
- Molecular imaging is a promising tool for noninvasive monitoring and quantification of fibrotic lung disease.
- Overcoming challenges in probe development and clinical translation is crucial for realizing its full potential.
- Further research and development are needed to expand the clinical utility of molecular imaging in pulmonary fibrosis and drug discovery.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

